7
Dianabol-Cycle%3A-FAQs-And-Harm-Reduction-Protocols.md
Normal file
7
Dianabol-Cycle%3A-FAQs-And-Harm-Reduction-Protocols.md
Normal file
@@ -0,0 +1,7 @@
|
|||||||
|
Dianabol Cycle: FAQs And Harm Reduction Protocols
|
||||||
|
<br>Clinical presentation / age of onset – MPS IIIa (Sanfilippo type A)<br>
|
||||||
|
<br>
|
||||||
|
FeatureWhat the literature says
|
||||||
|
Typical age when first signs appearThe article notes that symptoms "may be present early in life," but it does not provide a specific age range or average. In clinical practice, manifestations usually become apparent between 2–4 years of age (often earlier for more severe variants).
|
||||||
|
Early‑onset symptomsThe review lists the classic neuro‑cognitive phenotype—progressive intellectual decline and behavioral changes—but does not detail the earliest specific signs (e.g., speech delay, sleep disturbances).
|
||||||
|
Onset of motor/neurological deficitsNo age data is given
|
||||||
Reference in New Issue
Block a user